Switch theme
Sign up to access all valuation multiples
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
2018
43
Last FY Revenue n/a
LTM EBITDA -$84.3M
$175M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MBX Biosciences has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$84.3M.
In the most recent fiscal year, MBX Biosciences achieved revenue of n/a and an EBITDA of -$68.0M.
MBX Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MBX Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$84.3M | XXX | -$68.0M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$83.3M | XXX | -$68.2M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$77.2M | XXX | -$61.9M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, MBX Biosciences's stock price is $12.
MBX Biosciences has current market cap of $416M, and EV of $175M.
See MBX Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $175M | $416M | XXX | XXX | XXX | XXX | $-4.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, MBX Biosciences has market cap of $416M and EV of $175M.
MBX Biosciences's trades at n/a EV/Revenue multiple, and -2.6x EV/EBITDA.
Equity research analysts estimate MBX Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MBX Biosciences has a P/E ratio of -5.4x.
See valuation multiples for MBX Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $416M | XXX | $416M | XXX | XXX | XXX |
| EV (current) | $175M | XXX | $175M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.1x | XXX | -2.6x | XXX | XXX | XXX |
| EV/EBIT | -2.1x | XXX | -2.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.4x | XXX | -6.7x | XXX | XXX | XXX |
| EV/FCF | -2.3x | XXX | -3.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMBX Biosciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.6M for the same period.
MBX Biosciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MBX Biosciences's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MBX Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 36% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MBX Biosciences acquired XXX companies to date.
Last acquisition by MBX Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . MBX Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was MBX Biosciences founded? | MBX Biosciences was founded in 2018. |
| Where is MBX Biosciences headquartered? | MBX Biosciences is headquartered in United States of America. |
| How many employees does MBX Biosciences have? | As of today, MBX Biosciences has 43 employees. |
| Who is the CEO of MBX Biosciences? | MBX Biosciences's CEO is Mr. Peter Kent Hawryluk. |
| Is MBX Biosciences publicy listed? | Yes, MBX Biosciences is a public company listed on NAS. |
| What is the stock symbol of MBX Biosciences? | MBX Biosciences trades under MBX ticker. |
| When did MBX Biosciences go public? | MBX Biosciences went public in 2024. |
| Who are competitors of MBX Biosciences? | Similar companies to MBX Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of MBX Biosciences? | MBX Biosciences's current market cap is $416M |
| Is MBX Biosciences profitable? | Yes, MBX Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MBX Biosciences? | MBX Biosciences's last 12 months EBITDA is -$84.3M. |
| What is the current EV/EBITDA multiple of MBX Biosciences? | Current EBITDA multiple of MBX Biosciences is -2.1x. |
| What is the current FCF of MBX Biosciences? | MBX Biosciences's last 12 months FCF is -$77.7M. |
| What is the current EV/FCF multiple of MBX Biosciences? | Current FCF multiple of MBX Biosciences is -2.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
